Chemomab Therapeutics Ltd ADR
CMMBHealthcare·Biotechnology·USA·Nano·NASD·Nov 11 • 10:04 AM ET
1.41+0.06 (4.83%)
2026-11-11 16:05 CET
Market cap
9.75 USD m
Revenue, TTM
0.00 USD m
Net income, TTM
-7.61 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-1.02
P/E
-
Price
CMMB against its 20, 50 and 200-day averages2050200miss
56.3% under 3.23 on 30 Oct 2025. Last 15 sessions, 54.3% high to low
Profile
CMMB52-week range, 24% of the way up
0.922.99
Anchiano is a biopharmaceutical company that specializes in the development of Targeted Cancer Therapies for the treatment of numerous types of cancer. The Company's technology offers a safe and long-term treatment of cancer, with no adverse effects. BioCancell was co-founded in 2004 by Professor Avraham Hochberg, Professor of Molecular Biology at the Hebrew University of Jerusalem, based on technology developed by him over the past 25 years. The drug candidates developed by the Company are targeted and their goal is to selectively destroy the cancer cells without affecting healthy cells ('Targeted Cancer Therapy'). The approach is based on the identification of target genes, such as H19, that are expressed only in cancerous tumors, and not in healthy cells, and on the use of those genes' regulatory sequences for the activation of a toxin inside the cancerous cells only, thus destroying them without harming healthy cells. BioCancell's leading drug candidate, BC-819, has completed a Phase IIb clinical trial for the treatment of bladder cancer, as well as additional clinical trials for other cancer indications. BioCancell's Phase I clinical trial for BC-821, scheduled to commence in 2015, is a continuation of the success of pre-clinical studies that have examined the use of BC-821 as a treatment for several cancer indications
| Employees | 12 |
|---|---|
| IPO | Feb 12, 2019 |
| Beta | 0.76 |
| ATR, 14d | 0.15 |
| Rel volume | 0.16 |
| Short float | 0.07% |
| Insider own | 4.53% |
| Inst own | 5.86% |
Snapshot
6 groupsValuation
| Index | - |
|---|---|
| Market Cap | 10.22M |
| Enterprise Value | 3.53M |
| Income | -7.61M |
| Sales | 0.00M |
| Book/sh | 1.20 |
| Cash/sh | 0.92 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 12 |
| IPO | Feb 12, 2019 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | - |
| P/B | 1.18 |
| P/C | 1.53 |
| P/FCF | - |
| EV/EBITDA | - |
| EV/Sales | - |
| Quick Ratio | 6.41 |
| Current Ratio | 6.41 |
| Debt/Eq | 0.00 |
| LT Debt/Eq | 0.00 |
| Option/Short | No / Yes |
Earnings
| EPS (ttm) | -1.02 |
|---|---|
| EPS next Y | - |
| EPS next Q | - |
| EPS this Y | - |
| EPS next Y | - |
| EPS next 5Y | - |
| EPS past 3/5Y | 47.24% 43.73% |
| Sales past 3/5Y | - - |
| EPS Y/Y TTM | 56.99% |
| Sales Y/Y TTM | - |
| EPS Q/Q | 24.16% |
| Sales Q/Q | - |
| Earnings | Aug 19 BMO |
| EPS/Sales Surpr. | 98.00% - |
Ownership
| Insider Own | 4.53% |
|---|---|
| Insider Trans | -0.70% |
| Inst Own | 5.86% |
| Inst Trans | 8.25% |
| ROA | -71.19% |
| ROE | -82.74% |
| ROIC | -87.57% |
| Gross Margin | - |
| Oper. Margin | - |
| Profit Margin | - |
| SMA20 | 18.53% |
| SMA50 | -17.26% |
| SMA200 | -18.84% |
| Trades | - |
Technical
| Shs Outstand | 7.25M |
|---|---|
| Shs Float | 6.92M |
| Short Float | 0.07% |
| Short Ratio | 0.05 |
| Short Interest | 0.01M |
| 52W High | 2.99 -52.84% |
| 52W Low | 0.92 53.23% |
| Volatility | 11.82% 11.59% |
| ATR (14) | 0.15 |
| RSI (14) | 55.24 |
| Beta | 0.76 |
| Rel Volume | 0.16 |
| Avg Volume | 98.18K |
| Volume | 2,156 |
Performance
| Perf Week | 14.63% |
|---|---|
| Perf Month | 13.70% |
| Perf Quarter | -25.79% |
| Perf Half Y | -18.97% |
| Perf YTD | -14.55% |
| Perf Year | -47.19% |
| Perf 3Y | -40.26% |
| Perf 5Y | -96.27% |
| Perf 10Y | - |
| Recom | 1.00 |
| Target Price | 5.00 |
| Prev Close | 1.35 |
| Price | 1.41 |
| Change % | 4.83% |
Analyst ratings
latest 3 of 3| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| May 13, 2024 | Initiated | MMaxim Group | Buy | $4 | +183.7% |
| May 06, 2024 | Upgrade | OOppenheimer | Perform → Outperform | $6 | +325.6% |
| Dec 19, 2023 | Resumed | RROTH MKM | Buy | $7 | +396.5% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| AGMB | AgomAb Therapeutics NV ADR | 345.24M |
| GALT | Galectin Therapeutics Inc | 338.85M |
| PLRX | Pliant Therapeutics Inc | 47.37M |
| ZURA | Zura Bio Ltd | 133.41M |
| VCRE | Vicore Pharma Holding AB ADR | 314.83M |
| MIRM | Mirum Pharmaceuticals Inc | 6.16B |
| TVRD | Tvardi Therapeutics Inc | 21.01M |
| AVTX | Avalo Therapeutics Inc | 468.94M |
| AKTX | Akari Therapeutics Plc ADR | 12.92M |
| GYRE | Gyre Therapeutics Inc | 499.35M |
Insider trading
2 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Cohen Neil Harris | Director | Aug 27 '26 | Sale | 2.85 | 1,304 | 3,716 | 34,000 | Sep 01 10:05 AM |
| Cohen Neil Harris | Director | Aug 28 '26 | Sale | 2.80 | 1,000 | 2,800 | 33,000 | Sep 01 10:05 AM |
News
latest 14 of 206- Chemomab Therapeutics and Scipher Medicine Announce SEC Registration Statement on Form S-4 Is Effective (GlobeNewswire)
- Chemomab Therapeutics to Present at H.C. Wainwright 28th Annual Global Investor Conference (GlobeNewswire)
- Chemomab Therapeutics Announces Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +9.42%
- Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis (GlobeNewswire) -28.88%
- Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
- Loading…
- Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
- Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
- Chemomab Therapeutics Announces Nebokitug Phase 2 SPRING Trial Results in Primary Sclerosing Cholangitis Published in the American Journal of Gastroenterology (GlobeNewswire)
- Chemomab to Participate in Oppenheimer's Movers in Rare Disease Summit (GlobeNewswire)
- Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire) -10.00%
- Chemomab Announces Multiple Presentations at AASLD The Liver Meeting 2025 Featuring Clinical Data from the Nebokitug Phase 2 Trial in Primary Sclerosing Cholangitis (GlobeNewswire)
- ALKS to Enter Sleep Disorder Market With $2.1B Avadel Acquisition (Zacks) -5.83%
- Best Momentum Stocks to Buy for Oct. 23 (Zacks)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q2 | 2026-08-19 | -0.003 | -0.150 | -0.111 | 0.00 | - | 2 |
| 2026Q1 | 2026-05-14 | -0.003 | 0.000 | -0.222 | 0.00 | - | 1 |
| 2025Q4 | 2026-03-19 | -0.003 | -0.040 | -0.241 | 0.00 | - | 1 |
| 2025Q3 | 2025-11-20 | -0.016 | -0.040 | -0.283 | 0.00 | - | 1 |
| 2025Q2 | 2025-08-14 | -0.016 | -0.040 | -0.363 | 0.00 | - | 1 |
| 2025Q1 | 2025-05-15 | -0.028 | -0.380 | -0.579 | 0.00 | - | 2 |
| 2024Q4 | 2025-03-03 | -0.032 | -0.227 | -0.634 | 0.00 | 0.00 | 3 |
| 2024Q3 | 2024-11-14 | -0.040 | -0.227 | -0.797 | 0.00 | 0.00 | 3 |
| 2024Q2 | 2024-08-21 | -0.052 | -0.413 | -1.012 | 0.00 | 0.00 | 3 |
| 2024Q1 | 2024-05-09 | -0.056 | -0.040 | -1.101 | 0.00 | 0.00 | 2 |
| 2023Q4 | 2024-03-07 | -0.052 | -0.080 | -1.062 | 0.00 | 0.00 | 2 |
| 2023Q3 | 2023-11-09 | -0.068 | -0.120 | -1.376 | 0.00 | 0.00 | 2 |
| 2023Q2 | 2023-08-14 | -0.144 | -0.160 | -2.842 | 0.00 | 0.00 | 1 |
| 2023Q1 | 2023-05-11 | -0.160 | -0.140 | -3.139 | 0.00 | 0.00 | 2 |
| 2022Q4 | 2023-03-31 | -0.160 | -0.160 | -2.837 | 0.00 | 0.00 | 2 |
| 2022Q3 | 2022-11-11 | -0.140 | -0.920 | -2.778 | 0.00 | 0.00 | 3 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2018FY | -67.200 | -62.720 | -87.087 | 0.00 | - |
| 2019FY | -76.160 | -84.800 | -63.199 | - | - |
| 2021FY | -0.240 | -1.413 | -4.803 | 0.00 | 0.00 |
| 2022FY | -0.480 | -0.500 | -9.680 | 0.00 | 0.00 |
| 2023FY | -0.412 | -0.460 | -8.224 | 0.00 | 0.00 |
| 2024FY | -0.172 | -0.280 | -3.122 | 0.00 | 0.00 |
| 2025FY | -0.018 | -0.080 | -0.020 | 0.00 | - |
| 2026FY | - | -0.020 | - | - | - |
| 2027FY | - | -0.030 | - | - | - |
| 2028FY | - | -0.040 | - | - | - |
| 2029FY | - | -0.040 | - | - | - |
| 2030FY | - | -0.040 | - | - | 36.18 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q3 | R | 2026-08-19 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | R | 2026-07-28 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | R | 2026-05-14 | 1 | 1 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | R | 2026-03-19 | 1 | 0 | 0 | -0.01 | -0.01 | -0.01 |
| 2026Q3 | E | 2026-08-19 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | E | 2026-07-28 | 1 | 0 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | E | 2026-05-14 | 1 | 1 | 0 | 0.00 | 0.00 | 0.00 |
| 2026Q3 | E | 2026-03-19 | 1 | 1 | 0 | -0.01 | -0.01 | -0.01 |
| 2026Q3 | E | 2025-11-20 | 1 | 0 | 0 | -0.04 | -0.04 | -0.04 |
| 2026Q3 | E | 2025-11-11 | 1 | 0 | 0 | -0.04 | -0.04 | -0.04 |
| 2026Q3 | E | 2025-11-10 | 1 | 0 | 0 | -0.04 | -0.04 | -0.04 |
| 2026Q3 | E | 2025-11-09 | 1 | 0 | 0 | -0.04 | -0.04 | -0.04 |
| 2026Q3 | E | 2025-11-08 | 1 | 0 | 0 | -0.04 | -0.04 | -0.04 |
| 2026Q3 | E | 2025-11-07 | 1 | 0 | 0 | -0.04 | -0.04 | -0.04 |
Estimate history
| EPS, annual | -875.981 | -87.087 | -63.199 | -25.209 | -4.803 | -9.68 | -8.224 | -3.122 | -1.422 | -1.0205 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | -1.012 | -0.797 | -0.634 | -0.579 | -0.363 | -0.283 | -0.241 | -0.222 | -0.275 | |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
| Sales, annual | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | |
| Shares, annual | 0.012 | 0.195 | 0.464 | 0.464 | 2.851 | 2.908 | 3.551 | 4.714 | 7.192 | 7.246 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 3.59 | 4.714 | 4.714 | 4.716 | 5.173 | 6.155 | 7.192 | 7.2 | 7.246 | |
| Period | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.07 | 0.05 | 0.07 | 0.06 | 0.03 | 0.08 | 0.28 | 0.07 |
| Gross Profit | 0.00 | -0.07 | -0.05 | -0.07 | -0.06 | -0.03 | -0.08 | -0.28 | -0.07 |
| Selling, General and Administrative Excl. Other | 7.96 | 9.57 | 14.76 | 25.33 | 28.36 | 12.34 | 10.96 | 19.33 | 12.93 |
| Research and Development | 4.15 | 5.81 | 11.33 | 18.27 | 16.85 | 6.30 | 3.81 | 13.35 | 7.49 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -7.96 | -9.64 | -14.81 | -25.39 | -28.42 | -12.38 | -11.04 | -19.61 | -12.99 |
| Interest Expense | - | - | - | - | - | 0.11 | 0.01 | 0.01 | 0.02 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.75 | 7.95 | 0.00 |
| Net Income Before Taxes | -7.61 | -9.07 | -14.01 | -24.16 | -28.07 | -12.49 | -11.69 | -27.21 | -13.45 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | -0.53 | 0.00 | 0.00 | 0.00 | 0.31 |
| Consolidated Net Income | -7.61 | -9.07 | -14.01 | -24.16 | -27.54 | -12.49 | -11.69 | -27.21 | -13.75 |
| Net Income From Continuing Operations | -7.61 | -9.07 | -14.01 | -24.16 | -27.54 | -12.49 | -11.69 | -27.21 | -13.75 |
| Net Income | -7.61 | -9.07 | -14.01 | -24.16 | -27.54 | -12.49 | -11.69 | -27.21 | -13.75 |
| EPS (Recurring) | -0.95 | -1.42 | -3.12 | -8.22 | -9.68 | -4.81 | -24.07 | -50.28 | -87.09 |
| EPS (Basic, Before Extraordinaries) | -1.02 | -1.42 | -3.12 | -8.22 | -9.68 | -4.80 | -25.21 | -63.20 | -87.09 |
| EPS (Diluted) | -1.02 | -1.42 | -3.12 | -8.22 | -9.68 | -4.80 | -25.21 | -63.20 | -87.09 |
| EBITDA | - | -9.57 | -14.76 | -25.33 | -28.36 | -12.34 | -10.96 | -19.33 | -12.93 |
| Non-Operating Income (Expense) | 0.36 | 0.58 | 0.80 | 1.23 | 0.35 | 0.00 | 0.11 | 0.35 | -0.43 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | - | 0.63 | 0.62 | 1.49 | 2.53 | 2.02 | -0.02 | 0.89 | 1.46 |
| Shares Outstanding | 7.25 | 7.19 | 4.71 | 3.55 | 2.91 | 2.85 | 0.46 | 0.46 | 0.19 |
| Market Capitalization | 9.75 | 9.75 | 34.13 | 6.33 | 36.64 | 78.69 | 51.35 | 41.55 | 41.11 |
Income statement, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling, General and Administrative Excl. Other | 2.28 | 1.84 | 1.99 | 1.85 | 2.31 | 3.47 | 3.24 | 3.72 |
| Research and Development | 1.16 | 0.92 | 1.10 | 0.96 | 1.31 | 2.48 | 2.43 | 2.84 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -2.28 | -1.84 | -1.99 | -1.85 | -2.31 | -3.47 | -3.24 | -3.72 |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -2.20 | -1.77 | -1.88 | -1.75 | -2.10 | -3.31 | -2.99 | -3.49 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -2.20 | -1.77 | -1.88 | -1.75 | -2.10 | -3.31 | -2.99 | -3.49 |
| Net Income From Continuing Operations | -2.20 | -1.77 | -1.88 | -1.75 | -2.10 | -3.31 | -2.99 | -3.49 |
| Net Income | -2.20 | -1.77 | -1.88 | -1.75 | -2.10 | -3.31 | -2.99 | -3.49 |
| EPS (Recurring) | -0.28 | -0.22 | -0.24 | -0.28 | -0.36 | -0.58 | -0.63 | -0.80 |
| EPS (Basic, Before Extraordinaries) | -0.28 | -0.22 | -0.24 | -0.28 | -0.36 | -0.58 | -0.63 | -0.80 |
| EPS (Diluted) | -0.28 | -0.22 | -0.24 | -0.28 | -0.36 | -0.58 | -0.63 | -0.80 |
| EBITDA | - | -1.84 | - | - | - | -3.47 | - | -3.72 |
| Non-Operating Income (Expense) | 0.08 | 0.08 | 0.10 | 0.10 | 0.21 | 0.16 | 0.25 | 0.23 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 0.09 | - | - | - | 0.08 | - | - | - |
| Shares Outstanding | 7.25 | 7.20 | 7.19 | 6.16 | 5.17 | 4.72 | 4.71 | 4.71 |
| Market Capitalization | 9.75 | 11.29 | 10.16 | 13.61 | 24.00 | 20.56 | 34.13 | 29.60 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 10.37 | 14.34 | 19.86 | 39.97 | 61.16 | 5.39 | 17.58 | 7.52 | 1.45 |
| Short Term Receivables | 0.19 | 0.26 | 0.00 | 0.46 | 0.18 | 0.00 | 0.64 | 3.40 | 0.09 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 2.86 | 1.43 | 1.04 | 1.31 | 1.35 | 0.72 | 0.00 | 0.00 | 0.05 |
| Total Current Assets | 13.42 | 16.04 | 20.90 | 41.74 | 62.69 | 6.12 | 18.21 | 10.92 | 1.59 |
| Net Property, Plant & Equipment | 0.18 | 0.54 | 0.70 | 0.59 | 0.70 | 0.01 | 1.36 | 0.38 | 0.22 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.06 | 0.00 | 0.13 | 0.12 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.21 | 0.39 | 0.56 | 0.73 | 0.91 | 0.05 | 0.06 | 1.34 | 0.28 |
| Total Assets | 13.81 | 16.96 | 22.15 | 43.06 | 64.35 | 6.18 | 19.76 | 12.76 | 2.09 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.11 | 0.08 | 0.12 | 0.11 | 0.18 | 0.39 | 0.00 | 0.00 |
| Accounts Payable | 0.48 | 0.67 | 0.52 | 1.69 | 1.34 | 0.68 | 0.88 | 0.40 | 0.16 |
| Other Current Liabilities | 0.99 | 2.44 | 4.25 | 4.94 | 1.21 | 1.73 | 2.86 | 2.35 | 2.54 |
| Total Current Liabilities | 1.48 | 3.22 | 4.84 | 6.75 | 2.65 | 2.59 | 4.12 | 2.75 | 2.70 |
| Long Term Debt | 0.00 | 0.21 | 0.32 | 0.09 | 0.24 | 0.02 | 0.73 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.21 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.48 | 3.43 | 5.15 | 6.84 | 2.89 | 2.60 | 4.85 | 2.96 | 2.70 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 12.33 | 13.54 | 17.00 | 36.22 | 61.47 | 3.58 | 14.91 | 9.80 | -0.61 |
| Total Shareholders Equity | 12.33 | 13.54 | 17.00 | 36.22 | 61.47 | 3.58 | 14.91 | 9.80 | -0.61 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 12.33 | 13.54 | 17.00 | 36.22 | 61.47 | 3.58 | 14.91 | 9.80 | -0.61 |
| Total Liabilities & Stockholders Equity | 13.81 | 16.96 | 22.15 | 43.06 | 64.35 | 6.18 | 19.76 | 12.76 | 2.09 |
| Book Value Per Share | 1.71 | 2.87 | 4.79 | 12.46 | 21.56 | 7.71 | 32.15 | 50.36 | -50.68 |
| Tangible Book Value Per Share | 1.71 | 2.87 | 4.79 | 12.46 | 21.56 | 7.71 | 32.15 | 50.36 | -50.68 |
| Full-Time Employees | 12 | 16 | 20 | 37 | 20 | 3 | 16 | 19 | 17 |
| Price to Book Ratio | 1.12 | 2.52 | 0.35 | 0.82 | 1.28 | 14.35 | 2.79 | 4.43 | - |
| Return on Assets | -58.92 | -71.64 | -74.09 | -51.27 | -35.41 | -90.16 | -168.34 | -185.25 | -255.48 |
| Return on Equity | -70.09 | -91.77 | -90.79 | -56.38 | -38.39 | -126.48 | -393.83 | -299.11 | -736.42 |
| Return on Invested Capital | -73.51 | -101.93 | -139.54 | -75.83 | -20.24 | -325.37 | -174.05 | -140.27 | - |
| Quick Ratio | 9.08 | 4.98 | 4.32 | 6.18 | 23.66 | 2.37 | 4.42 | 3.98 | 0.59 |
| Current Ratio | 9.08 | 4.98 | 4.32 | 6.18 | 23.66 | 2.37 | 4.42 | 3.98 | 0.59 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | - | -9.07 | -14.01 | -24.16 | -27.54 | -12.49 | -11.69 | -27.21 | -13.75 |
| Depreciation | - | 0.07 | 0.05 | 0.07 | 0.06 | 0.03 | 0.08 | 0.28 | 0.07 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Funds (Non Cash) | - | 0.63 | 0.62 | 1.49 | 3.20 | 2.02 | 0.22 | 5.79 | 2.92 |
| Funds from Operations | - | -8.36 | -13.34 | -22.60 | -24.28 | -10.43 | -11.39 | -21.14 | -10.76 |
| Extraordinary Item | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | - | -2.86 | -2.12 | -0.95 | 3.99 | -1.95 | -1.41 | 4.63 | -3.41 |
| Cash from Operating Activities | - | -11.22 | -15.46 | -23.55 | -20.29 | -12.38 | -12.80 | -16.51 | -14.18 |
| Capital Expenditures | - | -0.00 | 0.00 | -0.00 | -0.07 | -0.24 | -0.03 | -0.10 | -0.21 |
| Net Assets From Acquisitions | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.14 | 0.00 | 0.00 |
| Purchase or Sale of Investments | - | 5.44 | 2.31 | 15.84 | 19.52 | -45.98 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | - | 0.00 | 0.00 | 0.00 | 0.00 | -45.98 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | - | 5.44 | 2.31 | 15.84 | 19.52 | - | 0.00 | 0.00 | 0.00 |
| Other Uses | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | - | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | - | 5.43 | 2.31 | 15.84 | 19.46 | -45.22 | 0.10 | -0.10 | -0.21 |
| Cash Dividends Paid | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | - | 7.21 | 9.91 | 3.49 | 0.41 | 58.69 | 0.00 | 26.71 | 20.54 |
| Repurchase of Common Pref Stock | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | - | 7.21 | 9.91 | 3.49 | 0.41 | 58.69 | 0.00 | 26.71 | 20.54 |
| Proceedsfrom Stock Options | - | 0.00 | 0.00 | 0.58 | 0.00 | 58.68 | 0.00 | 26.71 | 20.54 |
| Issuance or Reduction of Debt, Net | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 |
| Change in Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | - | 0.00 | 0.00 | 0.00 | -1.21 | 2.43 | 0.30 | 0.00 | 0.00 |
| Other Financing Activities Uses | - | 0.00 | 0.00 | 0.00 | -1.21 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | - | 7.21 | 9.91 | 3.49 | -0.80 | 61.12 | 0.30 | 26.71 | 20.55 |
| Exchange Rate Effect | - | - | - | - | - | - | - | - | -0.02 |
| Net Change in Cash | - | 1.43 | -3.24 | -4.22 | -1.64 | 3.52 | -12.40 | 10.10 | 6.16 |
| Free Cash Flow | - | -11.22 | -15.46 | -23.55 | -20.36 | -12.62 | -12.84 | -16.61 | -14.39 |
Balance sheet, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 6.69 | 8.04 | 10.37 | 10.21 | 9.51 | 10.70 |
| Short Term Receivables | 0.00 | 3.43 | 0.19 | 0.00 | 0.00 | 1.27 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 3.27 | 0.00 | 2.86 | 1.72 | 1.10 | 0.00 |
| Total Current Assets | 9.96 | 11.47 | 13.42 | 11.93 | 10.61 | 11.98 |
| Net Property, Plant & Equipment | 0.16 | 0.17 | 0.18 | 0.19 | 0.22 | 0.50 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.12 | 0.17 | 0.21 | 0.25 | 0.30 | 0.34 |
| Total Assets | 10.24 | 11.81 | 13.81 | 12.37 | 11.13 | 12.82 |
| Short Term Debt Incl. Current Port. of LT Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.11 |
| Accounts Payable | 0.26 | 0.20 | 0.48 | 0.19 | 0.38 | 0.49 |
| Other Current Liabilities | 1.30 | 0.91 | 0.99 | 0.94 | 1.05 | 1.64 |
| Total Current Liabilities | 1.55 | 1.11 | 1.48 | 1.14 | 1.43 | 2.25 |
| Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.18 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.55 | 1.11 | 1.48 | 1.14 | 1.43 | 2.43 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 8.68 | 10.70 | 12.33 | 11.23 | 9.70 | 10.39 |
| Total Shareholders Equity | 8.68 | 10.70 | 12.33 | 11.23 | 9.70 | 10.39 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 8.68 | 10.70 | 12.33 | 11.23 | 9.70 | 10.39 |
| Total Liabilities & Stockholders Equity | 10.24 | 11.81 | 13.81 | 12.37 | 11.13 | 12.82 |
| Book Value Per Share | 1.20 | 1.49 | 1.71 | 1.82 | 1.87 | 2.20 |
| Tangible Book Value Per Share | 1.20 | 1.49 | 1.71 | 1.82 | 1.87 | 2.20 |
| Full-Time Employees | - | - | 12 | - | - | - |
| Price to Book Ratio | 1.12 | 0.92 | 0.90 | 1.40 | 2.47 | 1.98 |
| Return on Assets | -71.19 | -60.93 | -58.75 | -60.98 | -92.59 | -86.96 |
| Return on Equity | -82.74 | -71.16 | -69.89 | -73.63 | -120.76 | -112.99 |
| Return on Invested Capital | -25.36 | -16.53 | -15.28 | -15.58 | -21.65 | -31.27 |
| Quick Ratio | 6.41 | 10.31 | 9.08 | 10.49 | 7.42 | 5.33 |
| Current Ratio | 6.41 | 10.31 | 9.08 | 10.49 | 7.42 | 5.33 |
Cash flow, quarterly
| Metric | 2026Q2 | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 |
|---|
Revenue breakdown
| Revenue split | - |
|---|
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 0.07% | 0.0M | 6.9M | 98.93K |
| 2026-10-15 | 0.20% | 0.0M | 6.9M | 103.91K |
| 2026-09-30 | 0.15% | 0.0M | 6.9M | 181.16K |
| 2026-09-15 | 1.18% | 0.1M | 6.9M | 151.50K |
| 2026-08-31 | 1.48% | 0.1M | 6.9M | 144.73K |
| 2026-08-14 | 1.64% | 0.1M | 6.9M | 129.92K |
| 2026-07-31 | 2.26% | 0.2M | 6.9M | 128.41K |
| 2026-07-15 | 1.96% | 0.1M | 6.9M | 122.73K |
| 2026-06-30 | 2.08% | 0.1M | 6.9M | 42.37K |
| 2026-06-15 | 1.95% | 0.1M | 6.9M | 45.68K |
| 2026-05-29 | 0.56% | 0.0M | 6.9M | 45.68K |
| 2026-05-15 | 0.58% | 0.0M | 6.9M | 65.06K |
| 2026-04-30 | 0.69% | 0.0M | 6.9M | 68.38K |
| 2026-04-15 | 0.73% | 0.1M | 6.9M | 72.39K |
| 2026-03-31 | 0.73% | 0.0M | 6.5M | 76.25K |
| 2026-03-13 | 0.63% | 0.0M | 6.5M | 88.47K |
| 2026-02-27 | 0.99% | 0.1M | 5.5M | 94.81K |
| 2026-02-13 | 0.38% | 0.0M | 5.5M | 81.92K |
| 2026-01-30 | 0.30% | 0.0M | 5.5M | 82.61K |
| 2026-01-15 | 0.24% | 0.0M | 5.5M | 101.43K |
Option chain
expiry 2026-11-11| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| No option chain for this symbol. | ||||||||||
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-10 | SCHEDULE 13D | SEC | ||
| 2026-11-10 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-11-03 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-11-03 | SEC |
| 2026-10-30 | EFFECT | Effectiveness filing by commission order | SEC | |
| 2026-10-30 | DEFM14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-10-29 | S-4/A | SEC | ||
| 2026-10-19 | S-4/A | SEC | ||
| 2026-10-19 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-10-19 | SEC |
| 2026-09-30 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-09-30 | SEC |
| 2026-09-25 | S-4 | Registration statement for securities to be issued in business combination transactions | SEC | |
| 2026-09-09 | SCHEDULE 13D/A | SEC | ||
| 2026-09-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-08-27 | SEC |
| 2026-08-19 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-30 | SEC |
| 2026-08-13 | SCHEDULE 13G | SEC | ||
| 2026-08-12 | DRS | SEC | ||
| 2026-08-10 | SCHEDULE 13G/A | SEC | ||
| 2026-07-16 | SCHEDULE 13D | SEC | ||
| 2026-07-08 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-07-08 | SEC |
| 2026-06-03 | 3 | Initial statement of beneficial ownership of securities | 2026-06-01 | SEC |
| 2026-06-02 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-06-02 | SEC |
| 2026-06-01 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-29 | SEC |
| 2026-05-14 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-14 | SEC |
| 2026-05-06 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-05-06 | SEC |
| 2026-04-28 | 6-K | Current report of foreign issuer pursuant to Rules 13a-16 and 15d-16 | 2026-04-28 | SEC |
| 2026-04-10 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-04-10 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-04-10 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-04-10 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-04-10 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
| 2026-04-10 | 3 | Initial statement of beneficial ownership of securities | 2026-03-18 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 6.52K | 2 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| CITADEL ADVISORS LLC | 1.32% |
| ADAR1 Capital Management, LLC | 1.11% |
| KESTRA PRIVATE WEALTH SERVICES, LLC | 1.06% |
| Ikarian Capital, LLC | 0.72% |
| RHUMBLINE ADVISERS | 0.42% |
| Philadelphia Investment Partners, LLC | 0.31% |
| StoneX Group Inc. | 0.26% |
| XTX Topco Ltd | 0.22% |
| Lido Advisors, LLC | 0.20% |
| SmartHarvest Portfolios, LLC | 0.18% |
Funds
| Fund | % owned |
|---|---|
| Fidelity Nasdaq Composite Index Fund | 0.08% |
OakChart. CMMB. Cached 15 minutes.